Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 4th Translational Research Conference: Chronic Lymphocytic Leukemia of the European School of Hematology (ESH) took place on March 5-7, 2026, in Stockholm, Sweden. This meeting fostered scientific exchange between laboratory scientists and clinicians working on translational CLL research worldwide.
View all videos

ESH CLL 2026

The 4th Translational Research Conference: Chronic Lymphocytic Leukemia
05–07 March 2026 | Stockholm, Sweden

ESH CLL 2026

The 4th Translational Research Conference: Chronic Lymphocytic Leukemia
05–07 March 2026 | Stockholm, Sweden
The 4th Translational Research Conference: Chronic Lymphocytic Leukemia of the European School of Hematology (ESH) took place on March 5-7, 2026, in Stockholm, Sweden. This meeting fostered scientific exchange between laboratory scientists and clinicians working on translational CLL research worldwide.
View all videos

Latest Videos

View all
3:31
Epigenetic targeting and therapeutic potential of UVI5008 in CLL
Carmela Dell'Aversana • 13 Mar 2026
5:36
Positioning UVI5008 in treatment sequencing for CLL
Carmela Dell'Aversana • 13 Mar 2026
2:27
Epigenetic mechanisms and durability of response in CLL
Carmela Dell'Aversana • 13 Mar 2026
2:39
Therapy options after covalent BTK inhibitor failure in CLL
Gianluca Gaidano • 11 Mar 2026

BTK inhibitors

View all
2:45
Data supporting continuous BTKi therapy as SoC for patients with CLL
Kerry Rogers • 5 Mar 2026
1:40
Non-covalent BTK inhibitors in CLL: activity after covalent BTK inhibitors
Romain Guièze • 6 Mar 2026

BTK degraders

View all
2:19
Resistance to BTK degraders and combination strategies in CLL
Allison Cool • 6 Mar 2026
2:08
Future role of BTK degraders in CLL treatment
Justin Taylor • 6 Mar 2026

Venetoclax

View all
2:39
Therapy options after covalent BTK inhibitor failure in CLL
Gianluca Gaidano • 11 Mar 2026
1:20
Fixed-duration acalabrutinib combinations in CLL
Gianluca Gaidano • 11 Mar 2026

Immuno-Oncology

View all
5:36
Positioning UVI5008 in treatment sequencing for CLL
Carmela Dell'Aversana • 13 Mar 2026
2:27
Epigenetic mechanisms and durability of response in CLL
Carmela Dell'Aversana • 13 Mar 2026

Richter's transformation

View all
2:45
Genomic drivers and evolution of Richter’s transformation in CLL
Ferran Nadeu • 6 Mar 2026
2:11
Consensus guidelines for diagnosis, prognosis & clinical trials in Richter’s transformation
Adam Kittai • 6 Mar 2026
1:58
Key biomarkers for risk stratification in CLL
Anne-Sophie Michallet • 5 Mar 2026
3:28
Clonal evolution and genetic drivers of progression in CLL
Romain Guièze • 6 Mar 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals